Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

References

• World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019 [J]. Weekly Epidemiol Rec. 2019;94(8):85–104. http://www.who.int/wer .
   Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites [J]. PLoS Med. 2013;10(9):e1001517.
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244–56.
   PubMed Web of Science ®Google Scholar
• Chiba N, Morozumi M, Shouji M, et al. Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010–2013 [J]. Emerg Infect Dis. 2014;20(7):1132–39.
   PubMed Web of Science ®Google Scholar
• Ho PL, Law PY, Chiu SS. Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong [J]. Hum Vaccin Immunother. 2019;15:455–58.
   PubMed Web of Science ®Google Scholar
• Kaya Gursoy B, Beyazova U, Oguz MM, et al. Impact of PCV7 vaccination on nasopharyngeal carriage and antimicrobial resistance among children in Turkey [J]. J Infect Dev Ctries. 2019;13(3):227–32.
   PubMed Web of Science ®Google Scholar
• Eichler N, Reynolds E, Jackson C, et al. Invasive pneumococcal disease and serotype emergence in the Auckland region during the vaccine era 2009–16 [J]. J Prim Health Care. 2019;11(1):24–31.
   PubMed Web of Science ®Google Scholar
• Berical AC, Harris D, Dela Cruz CS, et al. Pneumococcal Vaccination Strategies. An Update and Perspective [J]. Ann Am Thorac Soc. 2016;13(6):933–44.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance [J]. Lancet Infect Dis. 2015;15(3):301–09.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study [J]. Lancet Respir Med. 2016;4(5):399–406.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study [J]. Lancet Infect Dis. 2015;15(5):535–43.
   PubMed Web of Science ®Google Scholar
• Kim GL, Seon SH, Rhee DK. Pneumonia and Streptococcus pneumoniae vaccine [J]. Arch Pharm Res. 2017;40:885–93.
   PubMed Web of Science ®Google Scholar
• Thompson A, Lamberth E, Severs J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults [J]. Vaccine. 2019;37(42):6201–07.
   PubMed Web of Science ®Google Scholar
• Hurley D, Griffin C, Young M, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age [J]. Clin Infect Dis. 2021; 73(7):e1489-e1497. doi:10.1093/cid/ciaa1045.
   Google Scholar
• Weinberger R, von Kries R, Van Der Linden M, et al. Invasive pneumococcal disease in children under 16 years of age: incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany [J]. Vaccine. 2018;36(4):572–77.
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study [J]. Lancet Infect Dis. 2016;16(6):703–11.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study [J]. Lancet Infect Dis. 2018;18(4):441–51.
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Paran Y, Bishara J, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study [J]. Vaccine. 2015;33(9):1135–42.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis [J]. PLoS One. 2017;12(5):e0177113.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine [J]. Pediatr Infect Dis J. 2013;32(3):203–07.
   PubMed Web of Science ®Google Scholar
• Henckaerts L, Desmet S, Schalck N, et al. The impact of childhood 13-valent pneumococcal conjugate vaccination on overall invasive pneumococcal disease, including the oldest old [J]. Acta Clin Belg. 2021 Aug;76(4):272–279.
   Web of Science ®Google Scholar
• Buades J, Losada I, Gonzalez-Moreno J, et al. Evolution, clinical and microbiological characteristics of invasive pneumococcal disease since the introduction of the pneumococcal conjugate vaccine 13-valent in adults over 18 years old [J]. Vaccines (Basel). 2021;9(2):93. doi:10.3390/vaccines9020093.
   PubMed Web of Science ®Google Scholar
• Slotved HC, Dalby T, Hoffmann S. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark [J]. Vaccine. 2016;34:769–74.
   PubMed Web of Science ®Google Scholar
• Singh J, Sundaresan S, Manoharan A, et al. Serotype distribution and antimicrobial susceptibility pattern in children</=5 years with invasive pneumococcal disease in India - a systematic review [j]. vaccine. 2017;35(35 Pt B):4501–4509.
   PubMed Web of Science ®Google Scholar
• Hjálmarsdóttir MÁ, Quirk SJ, Haraldsson G, et al. Comparison of serotype prevalence of pneumococci isolated from middle Ear, lower respiratory tract and invasive disease prior to vaccination in Iceland [J]. PLoS One. 2017;12(1):e0169210.
   PubMed Web of Science ®Google Scholar
• Kawaguchiya M, Urushibara N, Aung MS, et al. Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan [J]. New Microbes New Infect. 2016;9:66–72.
   PubMedGoogle Scholar
• Nakano S, Fujisawa T, Ito Y, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012–2014 [J]. Vaccine. 2016;34(1):67–76.
   PubMed Web of Science ®Google Scholar
• Ho PL, Chiu SS, Law PY, et al. Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 Streptococcus pneumoniae after introduction of children pneumococcal conjugate vaccination in Hong Kong [J]. Diagn Microbiol Infect Dis. 2015;81(2):145–48.
   PubMed Web of Science ®Google Scholar
• Janapatla RP, Su LH, Chen HH, et al. Epidemiology of culture-confirmed infections of Streptococcus pneumoniae (2012–2015) and nasopharyngeal carriage in children and households in Taiwan (2014–2015) [J]. J Med Microbiol. 2017;66(6):729–36.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang Q, Yao K, et al. Clinical characteristics and serotype distribution of invasive pneumococcal disease in pediatric patients from Beijing, China [J]. Eur J Clin Microbiol Infect Dis. 2021; 40(9), 1833–1842.
   PubMed Web of Science ®Google Scholar
• Oligbu G, Collins S, Djennad A, et al. Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000-June 30, 2016 [J]. Emerg Infect Dis. 2019;25(9):1708–18.
   PubMed Web of Science ®Google Scholar
• Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis [J]. J Infect. 2018;77(5):368–78.
   PubMed Web of Science ®Google Scholar
• Varon E, Cohen R, Bechet S, et al. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children [J]. Vaccine. 2015;33(46):6178–85.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Little BA, Finkelstein J, et al. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness [J]. Vaccine. 2017;35(32):4002–09.
   PubMed Web of Science ®Google Scholar
• Monali R, De Vita E, Mariottini F, et al. Impact of vaccination on invasive pneumococcal disease in Italy 2007–2017: surveillance challenges and epidemiological changes [J]. Epidemiol Infect. 2020;148:e187.
   PubMed Web of Science ®Google Scholar
• Nakano S, Fujisawa T, Ito Y, et al. Nationwide surveillance of paediatric invasive and non-invasive pneumococcal disease in Japan after the introduction of the 13-valent conjugated vaccine, 2015–2017 [J]. Vaccine. 2020;38(7):1818–24.
   PubMed Web of Science ®Google Scholar
• Rokney A, Ben-Shimol S, Korenman Z, et al. Emergence of Streptococcus pneumoniae serotype 12f after sequential introduction of 7- and 13-valent vaccines, Israel [J]. Emerg Infect Dis. 2018;24(3):453–61.
   PubMed Web of Science ®Google Scholar
• Janoir C, Lepoutre A, Gutmann L, et al. Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent pneumococcal conjugate vaccine implementation in France [J]. Open Forum Infect Dis. 2016;3(1):ofw020.
   PubMed Web of Science ®Google Scholar
• Ohkusu M, Takeuchi N, Ishiwada N, et al. Clonal spread of serotype 12F ST4846 Streptococcus pneumoniae [J]. J Med Microbiol. 2019;68(9):1383–90.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes [J]. Lancet Infect Dis. 2005;5:83–93.
   PubMed Web of Science ®Google Scholar
• Alari A, Chaussade H, Domenech De CM, et al. Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis [J]. BMC Med. 2016;14(1):211.
   PubMed Web of Science ®Google Scholar
• Ruiz-Contreras J, Picazo J, Casado-Flores J, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children [J]. Vaccine. 2017;35(35 Pt B):4646–51.
   PubMed Web of Science ®Google Scholar
• Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15 [J]. Lancet Glob Health. 2018;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Mukerji R, Briles DE. New strategy is needed to prevent pneumococcal meningitis [J]. Pediatr Infect Dis J. 2020;39(4):298–304.
   PubMed Web of Science ®Google Scholar
• Strachan RE, Snelling TL, Jaffé A. Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine [J]. Bull World Health Organ. 2013;91:167–73.
   PubMed Web of Science ®Google Scholar
• Zampoli M, Kappos A, Wolter N, et al. Etiology and incidence of pleural empyema in South African children [J]. Pediatr Infect Dis J. 2015;34(12):1305–10.
   PubMed Web of Science ®Google Scholar
• Saxena S, Atchison C, Cecil E, et al. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England [J]. J Infect. 2015;71(4):428–36.
   PubMed Web of Science ®Google Scholar
• Thorrington D, Andrews N, Stowe J, et al. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control [J]. BMC Med. 2018;16(1):13.
   PubMed Web of Science ®Google Scholar
• LeBlanc J, ElSherif M, Ye L, et al. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. [J] BMJ Open Respir Res. 2020;7(1). doi:10.1136/bmjresp-2019-000550 .
   Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults [J]. N Engl J Med. 2015;372(12):1114–25.
   PubMed Web of Science ®Google Scholar
• Bender Jeffrey M, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? [J]. Clin Infect Dis. 2008;46(9):1346–52.
   PubMed Web of Science ®Google Scholar
• Han SB, Kim JH, Kang JH, et al. Recent epidemiology of Streptococcus pneumoniae in nasopharynxes of Korean children with acute otitis media [J]. J Infect Chemother. 2017;23(3):136–41.
   PubMed Web of Science ®Google Scholar
• Koutouzis EI, Michos A, Koutouzi FI, et al. Pneumococcal Mastoiditis in Children Before and After the Introduction of Conjugate Pneumococcal Vaccines [J]. Pediatr Infect Dis J. 2016;35(3):292–96.
   PubMed Web of Science ®Google Scholar
• Quirk SJ, Haraldsson G, Erlendsdóttir H, et al. Effect of vaccination on pneumococci isolated from the nasopharynx of healthy children and the middle ear of children with otitis media in Iceland [J]. J Clin Microbiol. 2018;56(12): e01046-18.
   PubMed Web of Science ®Google Scholar
• Morales M, Ludwig G, Ercibengoa M, et al. Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain [J]. PLoS One. 2018;13(12):e0209048.
   PubMed Web of Science ®Google Scholar
• Ruiz-Contreras J, Del Amo M, Picazo J. Effects of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants aged 0 to 90 days in Madrid, Spain [J]. J Pediatric Infect Dis Soc. 2018;7:175–76.
   PubMed Web of Science ®Google Scholar
• Wen DN, Liu Y, Shi W, et al. A cross-sectional survey of non-PCV13 serotype streptococcus pneumoniae in hospitalized children with respiratory tract infection in a secondary hospital in western China [J]. Chin J Evid Based Pediatr. 2017;12:180–84.
   Google Scholar
• Prins-van Ginkel AC, Berbers GA, Grundeken LH, et al. Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era [J]. PLoS One. 2016;11(1):e0147437.
   PubMed Web of Science ®Google Scholar
• Gidding HF, McCallum L, Fathima P, et al. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia [J]. Vaccine. 2018;36(19):2650–56.
   PubMed Web of Science ®Google Scholar
• Akata K, Chang B, Yatera K, et al. The distribution and annual changes in the Streptococcus pneumoniae serotypes in adult Japanese patients with pneumococcal pneumonia from 2011 to 2015 [J]. J Infect Chemother. 2017;23(5):301–06.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Bradley JS, et al. Invasive pneumococcal disease in infants aged 0-60 days in the United States in the 13-valent pneumococcal conjugate vaccine era [J]. J Pediatric Infect Dis Soc. 2018;7(3):249–52.
   PubMed Web of Science ®Google Scholar
• Katoh S, Suzuki M, Ariyoshi K, et al. Serotype replacement in adult pneumococcal pneumonia after the introduction of seven-valent pneumococcal conjugate vaccines for children in Japan: a systematic literature review and pooled data analysis [J]. Jpn J Infect Dis. 2017;70(5):495–501.
   PubMed Web of Science ®Google Scholar
• Corcoran M, Vickers I, Mereckiene J, et al. The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect? [J]. Epidemiol Infect. 2017;145(11):2390–99.
   PubMed Web of Science ®Google Scholar
• Van Der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PloS One. 2019;14(8):e0220453. doi:10.1371/journal.pone.0220453.
   PubMed Web of Science ®Google Scholar
• Sempere J, De Miguel S, Gonzalez-Camacho F, et al. Clinical relevance and molecular pathogenesis of the emerging serotypes 22F and 33F of Streptococcus pneumoniae in Spain [J]. Front Microbiol. 2020;11:309. doi:10.3389/fmicb.2020.00309.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Krizova P, Valentiner-Branth P, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination [J]. Thorax. 2019;74(5):473–82.
   PubMed Web of Science ®Google Scholar
• Naucler P, Galanis I, Morfeldt E, et al. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations [J]. Clin Infect Dis. 2017;65(11):1780–89.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Grant LR, Weatherholtz RC, et al. Relating pneumococcal carriage among children to disease rates among adults before and after the introduction of conjugate vaccines [J]. Am J Epidemiol. 2016;183(11):1055–62.
   PubMed Web of Science ®Google Scholar
• Du -Q-Q, Zeng H-L, Yuan L, et al. One cross-sectional investigation revealed that non-vaccine serotypes of Streptococcus pneumoniae could be identified more frequently in elderly Chinese people. Vaccine. 2021;39(24):3304–09. 06 02. doi:10.1016/j.vaccine.2021.02.053.
   PubMed Web of Science ®Google Scholar
• Wattal C, Goel N, Byotra SP. Prevalence of pneumococcal serotypes in adults >/=50 years of age [J]. Indian J Med Microbiol. 2017;35:95–100.
   PubMed Web of Science ®Google Scholar
• Colijn C, Corander J, Croucher NJ. Designing ecologically optimized pneumococcal vaccines using population genomics [J]. Nat Microbiol. 2020;5:473–85.
   PubMed Web of Science ®Google Scholar
• Kim L, McGee L, Tomczyk S, et al. Biological and epidemiological features of antibiotic-resistant streptococcus pneumoniae in pre-and post-conjugate vaccine eras: a United States perspective [J]. Clin Microbiol Rev. 2016;29(3):525–52.
   PubMed Web of Science ®Google Scholar
• Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study [J]. Antimicrob Agents Chemother. 2012;56(3):1418–26.
   PubMed Web of Science ®Google Scholar
• So Hyun Kim J-HS, Ryeon Chung D, Thamlikitkul V, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. [J]. Antimicrob Agents Chemother. 2012;56(3):1418–26.
   PubMed Web of Science ®Google Scholar
• Mott MP, Caierao J, Cunha GR, et al. Emergence of serotype 19A Streptococcus pneumoniae after PCV10 associated with a ST320 in adult population, in Porto Alegre, Brazil [J]. Epidemiol Infect. 2019;147:e93.
   PubMed Web of Science ®Google Scholar
• Bao Y, Wang Q, Yao K, et al. The changing phenotypes and genotypes of invasive pneumococcal isolates from children in Shenzhen during 2013–2017 [J]. Vaccine. 2019;37(49):7248–55.
   PubMed Web of Science ®Google Scholar
• Corcoran M, Mereckiene J, Cotter S, et al. Invasive Streptococcus pneumoniae infections and vaccine failures in children in Ireland from the postvaccine era from 2007 to 2018 [J]. Pediatr Infect Dis J. 2020;39(4):339–44.
   PubMed Web of Science ®Google Scholar
• Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR) [J]. Hum Vaccin Immunother. 2018;14:2142–49.
   PubMed Web of Science ®Google Scholar
• Petra Spanelova J, Malisova L, Musilek M, et al. Whole genome sequencing of macrolide resistant Streptococcus pneumoniae serotype 19A sequence type 416 [J]. BMC Microbiol. 2020;20(1):224.
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Pai R, Crook DW, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States [J]. PLoS Pathog. 2007;3(11):e168.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, de Florentis D, Canepa P, et al. Epidemiological changes after PCV7 implementation in Italy: perspective for new vaccines [J]. Hum Vaccin. 2011;7:211–16.
   PubMed Web of Science ®Google Scholar
• Camara J, Cubero M, Martin-Galiano AJ, et al. Evolution of the beta-lactam-resistant Streptococcus pneumoniae PMEN3 clone over a 30 year period in Barcelona, Spain [J]. J Antimicrob Chemother. 2018;73(11):2941–51.
   PubMed Web of Science ®Google Scholar
• Pichon B, Ladhani SN, Slack M P E, et al. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales [J]. J Clin Microbiol. 2013 Mar ;51(3):820–827.
   Google Scholar
• Chochua S, Metcalf BJ, Li Z, et al. Invasive Serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015–2016 [J]. Emerg Infect Dis. 2017;23(6):922–30.
   PubMed Web of Science ®Google Scholar
• Johnston C, Campo N, Berge MJ, et al. Streptococcus pneumoniae, le transformiste [J]. Trends Microbiol. 2014;22(3):113–19.
   PubMed Web of Science ®Google Scholar
• Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an Oral Streptococcus [J]. mBio. 2020;11(3): e00937-20. doi:10.1128/mBio.00937-20.
   Web of Science ®Google Scholar
• Hanachi M, Kiran A, Cornick J, et al. Genomic Characteristics of Invasive Streptococcus pneumoniae Serotype 1 in New Caledonia Prior to the Introduction of PCV13 [J]. Bioinform Biol Insights. 2020;14:1177932220962106.
   Web of Science ®Google Scholar
• Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: systematic review and meta-analyses of randomised controlled trials [J]. Vaccine. 2016;34:703–13.
   PubMed Web of Science ®Google Scholar
• Wasserman M, Lucas A, Jones D, et al. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK [J]. Epidemiol Infect. 2018;146(14):1797–806.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews NJ, et al. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial [J]. Lancet Infect Dis. 2018;18(2):171–79.
   PubMed Web of Science ®Google Scholar
• Zhou H, He J, Wu B, et al. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants [J]. Hum Vaccin Immunother. 2018;14(6):1444–52.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 years [J]. Expert Opin Biol Ther. 2018;18:7–17.
   PubMed Web of Science ®Google Scholar
• Colichio GB, Oliveira GS, Rodrigues TC, et al. Efficacy of a protein vaccine and a conjugate vaccine against co-colonization with vaccine-type and non-vaccine type pneumococci in mice [J]. Pathogens. 2020;9(4). doi:10.3390/pathogens9040278 .
   PubMed Web of Science ®Google Scholar
• Converso TR, Assoni L, Andre GO, et al. The long search for a serotype independent pneumococcal vaccine [J]. Expert Rev Vaccines. 2020;19(1):57–70.
   PubMed Web of Science ®Google Scholar
• Masomian M, Ahmad Z, Gew LT, et al. Development of next generation Streptococcus pneumoniae vaccines conferring broad protection [J]. Vaccines (Basel). 2020;8(1). doi:10.3390/vaccines8010132 .
   PubMed Web of Science ®Google Scholar
• Scott NR, Mann B, Tuomanen EI, et al. Multi-valent protein hybrid pneumococcal vaccines: a strategy for the next generation of vaccines [J]. Vaccines (Basel). 2021;9(3). doi:10.3390/vaccines9030209 .
   Web of Science ®Google Scholar
• Castro JT, Oliveira GS, Nishigasako MA, et al. Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A [J]. PloS One. 2020;15(1):e0228055.
   PubMed Web of Science ®Google Scholar
• Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines [J]. Hum Vaccin Immunother. 2016;12:383–92.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement [J]. Lancet Infect Dis. 2019;19:e213–e220.
   PubMed Web of Science ®Google Scholar